SEC Comment Letter 0000000000-23-002301 to Vistagen Therapeutics, Inc. (VTGN) (CIK 0001411685) (VTGN)
Vistagen Therapeutics, Inc. (VTGN) (CIK 0001411685)
Date: March 9, 2023 · CIK: 0001411685 · Accession: 0000000000-23-002301
AI Filing Summary & Sentiment
File numbers found in text: 333-270232
Letter
United States securities and exchange commission logo March 9, 2023 Shawn Singh Chief Executive Officer Vistagen Therapeutics, Inc. 343 Allerton Avenue South San Francisco, CA 94080 Re:Vistagen Therapeutics, Inc. Registration Statement on Form S-3 Filed March 2, 2023 File No. 333-270232 Dear Shawn Singh: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jack Kennedy, Esq.
Show Raw Text
United States securities and exchange commission logo
March 9, 2023
Shawn Singh
Chief Executive Officer
Vistagen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, CA 94080
Re:Vistagen Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 2, 2023
File No. 333-270232
Dear Shawn Singh:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jack Kennedy, Esq.